TY - JOUR T1 - Sclerotherapy for Orbital Lymphangioma – Case Series and Literature Review JF - In Vivo JO - In Vivo SP - 263 LP - 266 VL - 31 IS - 2 AU - KARNESH CHANDRAKANT PATEL AU - GEORGE KALANTZIS AU - NABIL EL-HINDY AU - BERNARD Y. CHANG Y1 - 2017/03/01 UR - http://iv.iiarjournals.org/content/31/2/263.abstract N2 - Orbital lymphangioma is a lymphatic system lesion that commonly presents in childhood. Management of these lesions is complex. Sclerotherapy is a therapy used to treat and shrink lesions prior to or as an alternative to surgery. We present three cases of orbital lymphangioma that were treated with sclerotherapy. Case 1: A 6-month-old boy was presented in 2010 with right ptosis and proptosis. Magnetic resonance imaging (MRI) identified a lesion involving the right orbit and face. Case 2: A 3-year-old girl was presented in 2011 with intermittent right periorbital swelling and medial canthal bleeding. MRI identified a soft-tissue lesion in the right orbit, extending into the face. Case 3: A 3-year-old girl was presented in 2012 with vomiting, and painful right proptosis. MRI identified an intra-conal lesion in the right orbit with fluid filled levels. All three patients were treated with sclerotherapy (sodium tetradecylsulfate). Sclerotherapy is a promising treatment for orbital lymphangioma. Its use may prevent the need for, or minimise the amount of surgical management. Several sclerosants are now commonly used to treat these lesions. ER -